BRPI0413574A - aplicação de polipeptìdeos da famìlia cupredoxina na terapia do cáncer - Google Patents
aplicação de polipeptìdeos da famìlia cupredoxina na terapia do cáncerInfo
- Publication number
- BRPI0413574A BRPI0413574A BRPI0413574-1A BRPI0413574A BRPI0413574A BR PI0413574 A BRPI0413574 A BR PI0413574A BR PI0413574 A BRPI0413574 A BR PI0413574A BR PI0413574 A BRPI0413574 A BR PI0413574A
- Authority
- BR
- Brazil
- Prior art keywords
- application
- cancer therapy
- cytotoxic factors
- family polypeptides
- methods
- Prior art date
Links
- 238000011275 oncology therapy Methods 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 108010092351 cupredoxin Proteins 0.000 title 1
- 239000003145 cytotoxic factor Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 230000030833 cell death Effects 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 230000017074 necrotic cell death Effects 0.000 abstract 1
- 230000004222 uncontrolled growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/80—Cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/415—Cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
"APLICAçãO DE POLIPEPTìDEOS DA FAMìLIA CUPREDOXINA NA TERAPIA DO CáNCER". São revelados fatores citotóxicos tendo aplicação na modulação da morte celular, e sua aplicação em métodos para tratar condições relacionadas com necroses ou apoptose. A invenção também refere-se a métodos para identificar agentes ativos úteis para tratar condições relacionadas com morte celular ou crescimento descontrolado. Os inventores presentes descobriram que diferentes microorganismos produzem diferentes fatores citotóxicos tendo atividade anticancerígena. Os fatores citotóxicos essencialmente puros podem ser usados em um método para tratar uma doença infecciosa ou um câncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41455003P | 2003-08-15 | 2003-08-15 | |
| US10/720,603 US7491394B2 (en) | 2001-02-15 | 2003-11-24 | Cytotoxic factors for modulating cell death |
| PCT/US2004/025982 WO2005018662A1 (en) | 2003-08-15 | 2004-08-10 | Use of polypeptides of the cupredoxin family in cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0413574A true BRPI0413574A (pt) | 2006-10-17 |
Family
ID=34221130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0413574-1A BRPI0413574A (pt) | 2003-08-15 | 2004-08-10 | aplicação de polipeptìdeos da famìlia cupredoxina na terapia do cáncer |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US7491394B2 (pt) |
| EP (2) | EP1653990B1 (pt) |
| JP (1) | JP2007502818A (pt) |
| KR (1) | KR20060098358A (pt) |
| AP (1) | AP2006003537A0 (pt) |
| AT (1) | ATE470672T1 (pt) |
| AU (1) | AU2004266632A1 (pt) |
| BR (1) | BRPI0413574A (pt) |
| CA (1) | CA2535581A1 (pt) |
| DE (1) | DE602004027637D1 (pt) |
| EA (1) | EA009897B1 (pt) |
| EC (1) | ECSP066422A (pt) |
| GE (1) | GEP20105022B (pt) |
| IL (1) | IL173576A0 (pt) |
| NO (1) | NO20061168L (pt) |
| NZ (1) | NZ545355A (pt) |
| OA (1) | OA13308A (pt) |
| TN (1) | TNSN06059A1 (pt) |
| WO (1) | WO2005018662A1 (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9096663B2 (en) * | 2001-02-15 | 2015-08-04 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof |
| US7491394B2 (en) | 2001-02-15 | 2009-02-17 | The Board Of Trustees Of The University Of Illinois | Cytotoxic factors for modulating cell death |
| US7338766B2 (en) | 2001-02-15 | 2008-03-04 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating malaria with cupredoxin and cytochrome |
| US7381701B2 (en) | 2001-02-15 | 2008-06-03 | The Borad Of Trustees Of The University Of Illinois | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins |
| US7556810B2 (en) | 2005-07-19 | 2009-07-07 | The Board Of Trustees Of The University Of Ilinois | Compositions and methods to control angiogenesis with cupredoxins |
| US7618939B2 (en) * | 2001-02-15 | 2009-11-17 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to prevent cancer with cupredoxins |
| US9434770B2 (en) * | 2004-10-07 | 2016-09-06 | Tapas K Das Gupta | Modified cupredoxin derived peptides |
| US9968685B2 (en) | 2004-10-07 | 2018-05-15 | Brad N. Taylor | Methods to treat cancer with cupredoxins |
| US8232244B2 (en) | 2007-02-08 | 2012-07-31 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to prevent cancer with cupredoxins |
| UA97466C2 (ru) | 2004-10-07 | 2012-02-27 | Ананда Чакрабарти | Транспортирующие соединения - производные купредоксина и способы их применения |
| US10675326B2 (en) | 2004-10-07 | 2020-06-09 | The Board Of Trustees Of The University Of Illinois | Compositions comprising cupredoxins for treating cancer |
| AU2006251742A1 (en) * | 2005-05-20 | 2006-11-30 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating malaria with cupredoxin and cytochrome |
| JP2008545398A (ja) * | 2005-05-20 | 2008-12-18 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | キュプレドキシンおよびシトクロムcを用いてhiv感染を治療するための組成物および方法 |
| AU2006277009A1 (en) * | 2005-05-20 | 2007-02-15 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins |
| WO2007024368A2 (en) * | 2005-07-19 | 2007-03-01 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to control angiogenesis with cupredoxins |
| EP1904642A4 (en) | 2005-07-19 | 2008-11-26 | Univ Illinois | TRANSPORT AGENTS FOR CROSS-BREAKING BLOOD-BRAIN DISEASE AND INTRUSION IN BRAIN CANCER CELLS AND METHOD OF USE THEREOF |
| US10266868B2 (en) | 2006-05-19 | 2019-04-23 | The Board Of Trustees Of The University Of Illinois | Compositions for treating HIV infection with cupredoxin and cytochrome C |
| BRPI0715027A2 (pt) * | 2006-09-11 | 2013-05-28 | Univ Illinois | modificaÇÕes dos peptÍdeos derivados da cupredoxina e seus mÉtodos de utilizaÇço |
| EP2061498A4 (en) * | 2006-09-14 | 2009-11-04 | Univ Illinois | COMPOSITIONS AND METHOD FOR CANCER PREPARATION WITH CUPREDOXINES |
| AU2007329375A1 (en) | 2006-12-04 | 2008-06-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to treat cancer with cupredoxins and CpG rich DNA |
| WO2008086523A2 (en) * | 2007-01-11 | 2008-07-17 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof |
| CA2734363C (en) * | 2008-09-18 | 2016-10-25 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| ES2786253T3 (es) | 2013-03-14 | 2020-10-09 | Immusoft Corp | Métodos para la diferenciación y transducción in vitro de células b de memoria con vectores virales pseudotipados vsv-g |
| EP4177336A1 (en) | 2014-12-19 | 2023-05-10 | Immusoft Corporation | B cells for in vivo delivery of therapeutic agents |
| WO2016176573A1 (en) * | 2015-04-30 | 2016-11-03 | Board Of Regents, The University Of Texas System | Antibacterial polypeptide libraries and methods for screening the same |
| CN111705026B (zh) * | 2020-06-02 | 2021-11-26 | 华中农业大学 | 一种牛支原体Mbov_0280基因突变株及其应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4585644A (en) | 1984-06-04 | 1986-04-29 | Phillips Petroleum Company | Changing oil tubes in a carbon black reactor |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US5827934A (en) * | 1988-03-08 | 1998-10-27 | The University Of Wyoming | Cytotoxic diphtheria toxin fragments |
| DK0737750T3 (da) | 1989-03-21 | 2003-09-01 | Vical Inc | Ekspression af exogene polynucleotidsekvenser i vertebrater |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5407683A (en) * | 1990-06-01 | 1995-04-18 | Research Corporation Technologies, Inc. | Pharmaceutical solutions and emulsions containing taxol |
| ATE295895T1 (de) | 1992-03-11 | 2005-06-15 | Powderject Vaccines Inc | Genetischer impfstoff gegen den immunschwäche virus |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| DE69418699T2 (de) | 1993-01-11 | 1999-09-30 | Dana-Farber Cancer Institute, Boston | Induktion der antworten zytotoxischer t-lymphozyten |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5789389A (en) * | 1995-03-17 | 1998-08-04 | Board Of Trustees Of University Of Illinois | BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs |
| US5972899A (en) * | 1996-01-25 | 1999-10-26 | New York University | Apoptosis induced by Shigella IpaB |
| US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| US7491394B2 (en) | 2001-02-15 | 2009-02-17 | The Board Of Trustees Of The University Of Illinois | Cytotoxic factors for modulating cell death |
| US7301010B2 (en) | 2001-02-15 | 2007-11-27 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating HIV infection with cupredoxin and cytochrome c |
| WO2002076380A2 (en) | 2001-02-15 | 2002-10-03 | The Board Of Trustees Of The University Of Illinois | Cytotoxic factors for modulating cell death |
| US7338766B2 (en) | 2001-02-15 | 2008-03-04 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating malaria with cupredoxin and cytochrome |
| UA88272C2 (ru) | 2003-08-15 | 2009-10-12 | Борд Оф Трастиз Оф Зе Юниверсити Оф Иллинойс | Применение полипептидов семейства купредоксина в лечении рака |
| UA97466C2 (ru) | 2004-10-07 | 2012-02-27 | Ананда Чакрабарти | Транспортирующие соединения - производные купредоксина и способы их применения |
| AU2006251742A1 (en) | 2005-05-20 | 2006-11-30 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating malaria with cupredoxin and cytochrome |
| JP2008545398A (ja) | 2005-05-20 | 2008-12-18 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | キュプレドキシンおよびシトクロムcを用いてhiv感染を治療するための組成物および方法 |
| EP1904642A4 (en) | 2005-07-19 | 2008-11-26 | Univ Illinois | TRANSPORT AGENTS FOR CROSS-BREAKING BLOOD-BRAIN DISEASE AND INTRUSION IN BRAIN CANCER CELLS AND METHOD OF USE THEREOF |
-
2003
- 2003-11-24 US US10/720,603 patent/US7491394B2/en not_active Expired - Lifetime
-
2004
- 2004-08-10 DE DE602004027637T patent/DE602004027637D1/de not_active Expired - Lifetime
- 2004-08-10 AU AU2004266632A patent/AU2004266632A1/en not_active Abandoned
- 2004-08-10 CA CA002535581A patent/CA2535581A1/en not_active Abandoned
- 2004-08-10 OA OA1200600056A patent/OA13308A/en unknown
- 2004-08-10 EA EA200600424A patent/EA009897B1/ru not_active IP Right Cessation
- 2004-08-10 GE GEAP20049294A patent/GEP20105022B/en unknown
- 2004-08-10 EP EP04780764A patent/EP1653990B1/en not_active Expired - Lifetime
- 2004-08-10 WO PCT/US2004/025982 patent/WO2005018662A1/en not_active Ceased
- 2004-08-10 BR BRPI0413574-1A patent/BRPI0413574A/pt not_active IP Right Cessation
- 2004-08-10 NZ NZ545355A patent/NZ545355A/en unknown
- 2004-08-10 JP JP2006523922A patent/JP2007502818A/ja active Pending
- 2004-08-10 AT AT04780764T patent/ATE470672T1/de not_active IP Right Cessation
- 2004-08-10 EP EP10156218A patent/EP2263682A1/en not_active Withdrawn
- 2004-08-10 AP AP2006003537A patent/AP2006003537A0/xx unknown
- 2004-08-10 KR KR1020067002935A patent/KR20060098358A/ko not_active Abandoned
-
2006
- 2006-02-07 IL IL173576A patent/IL173576A0/en unknown
- 2006-02-15 TN TNP2006000059A patent/TNSN06059A1/en unknown
- 2006-03-13 NO NO20061168A patent/NO20061168L/no not_active Application Discontinuation
- 2006-03-15 EC EC2006006422A patent/ECSP066422A/es unknown
- 2006-08-23 US US11/508,173 patent/US7888468B2/en not_active Expired - Fee Related
- 2006-08-25 US US11/509,682 patent/US20080182782A1/en not_active Abandoned
-
2013
- 2013-11-08 US US14/075,994 patent/US10421801B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7491394B2 (en) | 2009-02-17 |
| EP1653990A1 (en) | 2006-05-10 |
| ECSP066422A (es) | 2006-11-24 |
| US20060292136A1 (en) | 2006-12-28 |
| ATE470672T1 (de) | 2010-06-15 |
| CA2535581A1 (en) | 2005-03-03 |
| EP1653990B1 (en) | 2010-06-09 |
| AP2006003537A0 (en) | 2006-04-30 |
| TNSN06059A1 (en) | 2007-10-03 |
| KR20060098358A (ko) | 2006-09-18 |
| US20140179617A1 (en) | 2014-06-26 |
| US20080182782A1 (en) | 2008-07-31 |
| DE602004027637D1 (de) | 2010-07-22 |
| JP2007502818A (ja) | 2007-02-15 |
| EA200600424A1 (ru) | 2006-08-25 |
| WO2005018662A1 (en) | 2005-03-03 |
| GEP20105022B (en) | 2010-06-25 |
| IL173576A0 (en) | 2006-07-05 |
| US10421801B2 (en) | 2019-09-24 |
| NO20061168L (no) | 2006-05-15 |
| EA009897B1 (ru) | 2008-04-28 |
| NZ545355A (en) | 2009-10-30 |
| US7888468B2 (en) | 2011-02-15 |
| OA13308A (en) | 2007-04-13 |
| US20060040269A1 (en) | 2006-02-23 |
| EP2263682A1 (en) | 2010-12-22 |
| AU2004266632A1 (en) | 2005-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03006771A (es) | Anticuerpos modificados y metodos de uso. | |
| TNSN06059A1 (en) | Use of polypeptides of the cupredoxin family in cancer therapy | |
| BR0110420A (pt) | Agonistas muscarìnicos | |
| ATE200677T1 (de) | Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase | |
| TR201903587T4 (tr) | Telomeraz aktivitesinin artırılması için bileşimler. | |
| GEP20022804B (en) | Erythropoietin Derivatives | |
| ATE448686T1 (de) | Actriib-fusionspolypeptide und verwendungen dafür | |
| GEP20043363B (en) | Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation | |
| ES2158115T3 (es) | Derivados de histidina y homohistidina como inhibidores de la farnesiltransferasa de proteinas. | |
| BRPI0414455A (pt) | métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins | |
| NO20025450D0 (no) | Ny farmasöytisk sammensetning | |
| BR0212809A (pt) | Inibidores de anticorpos de gdf-8 e usos dos mesmos | |
| DK155143C (da) | Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet | |
| BRPI0408256A (pt) | composto, métodos de tratamento de um humano ou animal, pela limitação da replicação de células, que sofre de cáncer, que sofre de uma doença neoplástica, e que se sofre de doenças proliferativas, uso de um composto, e, processo para a preparação de um composto ou de um seu sal farmaceuticamente aceitável ou de um éster hidrolisável in vivo do mesmo | |
| ATE415962T1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
| EP1461313A4 (en) | INHIBITORS OF HUMAN ADAM-10 | |
| BR9908510A (pt) | Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana | |
| ATE461707T1 (de) | Pharmazeutische verbindung und methoden zur behandlungen von menschliche karzinome mittels arginin entzug | |
| DE69935853D1 (de) | Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten | |
| BRPI0612840A8 (pt) | Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções | |
| BR0214196A (pt) | Método e composição para reduzir a atividade de inibir o crescimento de uma célula cancerosa, para tratar de paciente com câncer | |
| DE69934987D1 (de) | Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen | |
| WO2024026308A3 (en) | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPα) GENE | |
| BR0311371A (pt) | Composições para uso terapêutico compreendendo uma vitamina, um sal de metal e insulina ou um hormÈnio de crescimento | |
| ATE406158T1 (de) | Verwendung von vitamin c zur behandlung der charcot-marie-tooth krankheit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2266 DE 10/06/2014. |